“Tumors located at the base of the skull are particularly challenging to treat due to the location of delicate anatomic structures and critical blood vessels,” said neurosurgeon Clark C. Chen, MD, PhD, UC San Diego Health System. “The conventional approach to excising these tumors involves long skin incisions and removal of a large piece of skull. …
Cancer Research UK scientists at The University of Manchester found that some melanoma cells are particularly fast growing, but not very good at invading the surrounding tissue, while other melanoma cells are the opposite — highly invasive but slow-growing. …
Researchers at the USDA/ARS Children’s Nutrition Research Center at Baylor College of Medicine and Texas Children’s Hospital have now created a mouse model providing the first in vivo evidence that epigenetic alterations alone can cause cancer. Their report appears in the Journal of Clinical Investigation…
“Although the effects of the drug were modest, we now know that we can influence the course of the disease, and we expect to build on this success with other drugs, including some already in development,” said senior author, Gary K. Schwartz, MD, professor of medicine and chief of hematology/oncology at NewYork-Presbyterian/Columbia University Medical Center and associate director of its Herbert Irving Comprehensive Cancer Center. (At the time of the trial, Dr. Schwartz was chief of the melanoma and sarcoma service at Memorial Sloan Kettering Cancer Center in New York.) Uveal melanoma is a cancer of the iris, ciliary body, or choroid — structures in the eye collectively known as the uvea…
When researchers dialed up mutant Kras to spur pancreatic cancer growth in mice, and then shut it down, a group of recurrent tumors grew back independently of mutant Kras, reliant on a different oncogene. …
“We found that the use of low-dose aspirin was associated with cutting the risk of pancreatic cancer in half, with some evidence that the longer low-dose aspirin was used, the lower the risk,” said Harvey A. Risch, MD, PhD, professor of epidemiology in the Department of Chronic Disease Epidemiology at the Yale School of Public Health in New Haven, Connecticut…
Every year 8,800 people are diagnosed with the disease in the UK but survival rates remain very low, with only three per cent of people diagnosed with pancreatic cancer surviving their disease for five years or more after their diagnosis. Cancer Research UK has made pancreatic cancer research a priority, and has the bold ambition to more than double its annual spend of £6million on research into the disease over the next five years. The charity is investing in fundamental biology investigating how the cancer spreads as well as trials looking at boosting the effectiveness of the standard chemotherapy treatments in pancreatic cancer patients. While more research is needed to find better ways of diagnosing and treating the disease, there is evidence to suggest that some pancreatic cancers are linked to being overweight and to smoking — and almost four in 10 could be prevented by lifestyle changes to address this…
The discovery is in part due to research into the genetics of humans’ most distant mammalian relative, the platypus. In a paper published today in the journal PLOS ONE, researchers characterize a genetic pathway — involving piRNA genes — that is turned on in ovarian cancer. “This pathway is important for the development of the ovaries in drosophila flies but little is known about its role in the mammalian ovary,” says lead author Associate Professor Frank Grützner, Genetics Lecturer and ARC Research Fellow with the University of Adelaide’s Robinson Research Institute and the School of Molecular and Biomedical Science. …
The findings come in a pair of studies published online this week in the journals Gynecologic Oncology and Molecular Cancer Therapeutics. Ovarian cancer is a leading cause of female cancer death in the United States…
Trebananib (formally known as AMG 386; Amgen) is a first-in-class peptide-Fc fusion protein (or peptibody) that targets angiogenesis (the growth of new blood vessels into cancerous tumors) by inhibiting the binding of both angiopoietin 1 and 2 to the Tie2 receptor. This is very different mechanism of action than other agents that also effect angiogenesis by inhibiting vascular endothelial growth factor (VEGF) such as bevacizumab (Avastin; Genentech). Trebananib does not increase the risks of hypertension (high blood pressure) and bowel perforation like bevaciuzmab, but still has a similar impact on tumor shrinkage and delaying cancer progression…